Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial
Autor: | Senan, S., Özgüroğlu, M., Daniel, D., Villegas, A., Vicente, D., Murakami, S., Hui, R., Faivre-Finn, C., Paz-Ares, L., Wu, Y.L., Mann, H., Dennis, P.A., Antonia, S.J. |
---|---|
Zdroj: | In ESMO Open April 2022 7(2) |
Databáze: | ScienceDirect |
Externí odkaz: |